Et åbent studie til evaluering af PF-07994525 hos deltagere med fremskredne kræftformer
Et åbent mærket Fase 1-studie til vurdering af PF-07994525 hos deltagere med fremskredne maligniteter
This is an open-label, dose escalation and dose expansion study evaluating the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and antitumor activity of PF-07994525 in participants with R/R MM.
The study will consist of 2 parts: Part 1 (Dose Escalation) will consist of PF-07994525 dose escalation to assess the safety, tolerability, and preliminary antitumor activity in participants with R/R MM. In Part 2 (Dose expansion), PF-07994525 may be evaluated in additional participants with R/R MM to further assess safety, PK, PD, and preliminary anti-tumor activity.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Pfizer CT.gov Call Center
- Telefonnummer: 1-800-718-1021
- E-mail: ClinicalTrials.gov_Inquiries@pfizer.com
Studiesteder
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 5G2
- Rekruttering
- Arthur J.E. Child Comprehensive Cancer Centre
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V 5C2
- Ikke rekrutterer endnu
- Juravinski Cancer Centre
-
Toronto, Ontario, Canada, M5G2M9
- Rekruttering
- University Health Network- Princess Margaret Cancer Centre
-
-
-
-
Colorado
-
Denver, Colorado, Forenede Stater, 80218
- Rekruttering
- Colorado Blood Cancer Institute
-
Denver, Colorado, Forenede Stater, 80218
- Rekruttering
- Presbyterian/St. Luke's Medical Center
-
-
Connecticut
-
New Haven, Connecticut, Forenede Stater, 06511
- Rekruttering
- Smilow Cancer Hospital Phase 1 Unit
-
New Haven, Connecticut, Forenede Stater, 06510
- Rekruttering
- Yale-New Haven Hospital-Yale Cancer Center
-
New Haven, Connecticut, Forenede Stater, 06510
- Rekruttering
- Smilow Cancer Hospital - Yale New Haven Health
-
New Haven, Connecticut, Forenede Stater, 06511
- Rekruttering
- Yale University - Smilow Cancer Hospital; C/O Thomas Ferencz, RPh, BCOP
-
North Haven, Connecticut, Forenede Stater, 06473
- Rekruttering
- Smilow Cancer Hospital - North Haven
-
-
Florida
-
Coral Gables, Florida, Forenede Stater, 33146
- Rekruttering
- Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center
-
Coral Springs, Florida, Forenede Stater, 33065
- Rekruttering
- Sylvester Comprehensive Cancer Center - Coral Springs
-
Deerfield Beach, Florida, Forenede Stater, 33442
- Rekruttering
- University of Miami Hospital and Clinics - Deerfield Beach
-
Doral, Florida, Forenede Stater, 33166
- Rekruttering
- Sylvester Comprehensive Cancer Center- Doral
-
Hollywood, Florida, Forenede Stater, 33021
- Rekruttering
- Sylvester Comprehensive Cancer Center - Hollywood
-
Miami, Florida, Forenede Stater, 33136
- Rekruttering
- Sylvester Comprehensive Cancer Center
-
Miami, Florida, Forenede Stater, 33136
- Rekruttering
- University of Miami Hospital and Clinics
-
Miami, Florida, Forenede Stater, 33176
- Rekruttering
- Sylvester Comprehensive Cancer Center- Kendall
-
North Miami, Florida, Forenede Stater, 33181
- Rekruttering
- Sylvester Comprehensive Cancer Center - Sole Mia
-
Plantation, Florida, Forenede Stater, 33324
- Rekruttering
- Sylvester Comprehensive Cancer Center - Plantation
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30308
- Rekruttering
- Emory University Hospital Midtown
-
Atlanta, Georgia, Forenede Stater, 30322
- Rekruttering
- Emory University Hospital
-
Atlanta, Georgia, Forenede Stater, 30322
- Rekruttering
- Winship Cancer Institute, Emory University
-
-
Ohio
-
Columbus, Ohio, Forenede Stater, 43210
- Rekruttering
- The James Cancer Hospital and Solove Research Institute
-
Columbus, Ohio, Forenede Stater, 43210
- Rekruttering
- Ohio State University Hospitals
-
Columbus, Ohio, Forenede Stater, 43210
- Rekruttering
- The James Outpatient Care West Campus
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37203
- Rekruttering
- Sarah Cannon Research Institute - Pharmacy
-
Nashville, Tennessee, Forenede Stater, 37203
- Rekruttering
- Tristar BMT
-
Nashville, Tennessee, Forenede Stater, 37203
- Rekruttering
- SCRI Oncology Partners
-
Nashville, Tennessee, Forenede Stater, 37203
- Rekruttering
- TriStar Centennial Medical center
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Participants aged 18 years or older (or the minimum age of consent in accordance with local regulations) at the time of informed consent.
- Prior diagnosis of MM as defined according to IMWG criteria (Rajkumar et al. 2014)
Measurable disease based on IMWG criteria as defined by at least 1 of the following:
-
Serum M-protein >0.5 g/dL by serum protein electrophoresis (SPEP)
-
Urinary M-protein excretion >200 mg/24 hours by urine protein electrophoresis (UPEP)
-
Serum immunoglobulin Free Light Chain (FLC) ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio (<0.26 or >1.65)
- Participants must be refractory to, or intolerant to, all established therapies known to provide clinical benefit in multiple myeloma that are an appropriate therapeutic option, in the judgement of the investigator. A minimum of 3 prior lines of therapy are required.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
Exclusion Criteria:
- Active plasma cell leukemia, Smoldering MM, Waldenströms macroglobulinemia, Amyloidosis, POEMS Syndrome.
- Autologous stem cell transplant within 12 weeks prior to enrollment or active Graft-versus-host disease (GVHD).
- Active or suspected cerebral/meningeal disease related to the underlying malignancy.
- Any active, uncontrolled bacterial, fungal, or viral infection, including (but not limited to) COVID-19, Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), known HIV or AIDS related illness, unless deemed not clinically significant by the investigator (eg, onychomycosis).
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Part 1
Monotherapy Dose Expansion |
Oral administration Oral administration |
|
Eksperimentel: Part 2
Monotherapy Dose Escalation |
Oral administration |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Type, incidence and severity of participants with adverse events (AEs)
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Type, incidence, severity (graded by National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] version 5.0), timing, seriousness, and relatedness of adverse events (AEs) |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Type, incidence and severity of participants with laboratory abnormalities
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Type, incidence, and severity (graded by NCI CTCAE version 5.0) of laboratory abnormalities |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Number of participants with dose modifications
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Frequency of dose modifications (eg, dose delay, treatment interruptions, dose reductions, and treatment discontinuations) due to AEs |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)
Tidsramme: Baseline to end of DLT evaluation period
|
Occurrence of DLTs as defined by the protocol |
Baseline to end of DLT evaluation period
|
|
Part 1: Recommended Monotherapy Dose for Expansion (RDE)
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
RDE will be based on cumulative safety, preliminary antitumor activity and pharmacokinetics findings |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Part 2: Recommended Dose for future development
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Safety, and preliminary anti-tumor activity |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Objektiv responsrate (ORR) ifølge International Myeloma Working Group (IMWG) responskriterier som fastsat af undersøgeren.
Tidsramme: Baseline indtil datoen for den første dokumentation af sygdomsprogression, død eller start på ny antikræftbehandling (cirka 2 år)
|
Baseline indtil datoen for den første dokumentation af sygdomsprogression, død eller start på ny antikræftbehandling (cirka 2 år)
|
|
|
Komplet responsrate (CRR) ifølge International Myeloma Working Group (IMWG) responskriterier som bestemt af undersøgeren.
Tidsramme: Baseline indtil datoen for den første dokumentation af sygdomsprogression, død eller start på ny antikræftbehandling (cirka 2 år)
|
Baseline indtil datoen for den første dokumentation af sygdomsprogression, død eller start på ny antikræftbehandling (cirka 2 år)
|
|
|
Tid til respons (TTR) ifølge IMWG som bestemt af undersøgeren
Tidsramme: Baseline indtil datoen for den første dokumentation af sygdomsprogression, død eller start på ny antikancerbehandling (ca. 2 år)
|
Baseline indtil datoen for den første dokumentation af sygdomsprogression, død eller start på ny antikancerbehandling (ca. 2 år)
|
|
|
Varigheden af respons (DOR) pr. IMWG som fastlagt af undersøgeren
Tidsramme: Fra baseline til datoen for den første dokumentation af sygdomsprogression, død eller start på ny antikraeftbehandling (cirka 2 år)
|
Fra baseline til datoen for den første dokumentation af sygdomsprogression, død eller start på ny antikraeftbehandling (cirka 2 år)
|
|
|
Varighed af komplet respons (DOCR) pr. IMWG som bestemt af undersøger
Tidsramme: Baseline indtil datoen for den første dokumentation af sygdomsprogression, død eller start på ny antikraeftbehandling (cirka 2 år)
|
Baseline indtil datoen for den første dokumentation af sygdomsprogression, død eller start på ny antikraeftbehandling (cirka 2 år)
|
|
|
Progression-fri overlevelse (PFS) pr. IMWG som fastsat af undersøgeren
Tidsramme: Baseline indtil datoen for den første dokumentation af sygdomsprogression, død eller start på ny antikraeftbehandling (ca. 2 år)
|
Baseline indtil datoen for den første dokumentation af sygdomsprogression, død eller start på ny antikraeftbehandling (ca. 2 år)
|
|
|
Samlet overlevelse (OS)
Tidsramme: Baseline indtil datoen for den første dokumentation af sygdomsprogression, død eller start på ny antikraeftbehandling (ca. 2 år)
|
Baseline indtil datoen for den første dokumentation af sygdomsprogression, død eller start på ny antikraeftbehandling (ca. 2 år)
|
|
|
Single, Multiple Dose and food effect: Maximum Observed Concentration (Cmax)
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single, Multiple Dose and food effect: Time to Maximum concentration (Tmax)
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single, Multiple Dose and food effect: AUC from time zero to time of last measurable concentration (AUClast)
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single Dose and food effect: Terminal Elimination half-life (t1/2) as data permit
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single Dose and food effect: AUC versus time curve from time 0 extrapolated to infinity (AUCinf) as data permit
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single, Multiple Dose and food effect: apparent clearance of drug (CL/F) as data permit
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single, Multiple Dose and food effect: Apparent volume of distribution during terminal phase (Vz/F) as data permit
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Multiple Dose: AUC at steady state over the dosing interval (AUCtau) as data permit
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Multiple Dose: Cmin as data permit
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Multiple Dose: Accumulation ratio (Rac) as data permit
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
AUC from time zero to time of last measurable concentration (AUClast)
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
PK parameters of CYP3A4 probe substrate midazolam with and without PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Time to Maximum concentration (Tmax)
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
PK parameters of CYP3A4 probe substrate midazolam with and without PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Maximum Observed Concentration (Cmax)
Tidsramme: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
PK parameters of CYP3A4 probe substrate midazolam with and without PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Pfizer CT.gov Call Center, Pfizer
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- C6331001
- KAT2i (Anden identifikator: Alias Study Number)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .